Clinical Results of Anterior Chamber Phakic Intraocular Lens

ABSTRACT

PURPOSE: To evaluate the efficacy, stability and complications of implantation of anterior chamber phakic intraocular lens (Phakic 6H) in myopic eyes. METHODS: We retrospectively analyzed 97 myopic eyes of 56 patients who were treated for moderate or high myopia with the implantation of Phakic 6H. Manifest refraction (MR), uncorrected (UCVA) and best corrected visual acuity (BCVA), intraocular pressure, cornea endothelium, possible complications, and subjective symptoms were evaluated. RESULTS: The mean patient age was 26.2 years (2.94 SD; range, 20 to 40 years). There was a statistically significant reduction in the spherical equivalent from -10.91D+/-3.07 (range -5.75D to -21.0D) to -0.96D+/-0.89 (range +0.75D to -2.5D) (p<0.001) at postoperative 6 months. The percentage of patients who had an UCVA of 0.6 better was 78.35%, and 34.02% had an UCVA of 1.0 or better at postoperative 6 months. Mean endothelial cell density was 2714+/-164 cell/mm2 prior to operation, with a-1.85% at 6 months. Glare and halo were observed in eight eyes (8.25%). Other complications were oval pupil (2.06%), hyphema (2.06%), decenterated IOL (9.28%), temporary increased IOP (6.17%). CONCLUSIONS: The anterior chamber phakic intraocular lens showed encouraging results in treating high myopia. However, additional patients and longer follow-up periods are needed to detect the long-term efficacy and safety of this refractive lens.